Elevation Oncology, Inc. ELEV
0.37 0.00 (+0.00%)
At closeJul 23, 2025, 4:00 PM EDT
0.365 Day range 0.365
0.44 52-week range 5.83
News
benzinga.com ' Medicare Part D Drug Plan Premiums Set to Rise'- WSJ https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c
benzinga.com 'Senate Republicans to Omit Medicare Advantage Cuts in Tax Bill'- Bloomberg https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true
globenewswire.com HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV) NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
prnewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
businesswire.com ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
benzinga.com This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday 
businesswire.com ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to…
prnewswire.com Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients…
benzinga.com 'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics
benzinga.com 'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&embedded-checkout=true
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
prnewswire.com Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 --…
prnewswire.com Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON , April 25, 2025…
prnewswire.com Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 -- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell…
zacks.com Elevation Oncology Plunges 42% on Ending Development of Lead Drug ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
prnewswire.com Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options -- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
prnewswire.com Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements -- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction…
prnewswire.com Elevation Oncology to Participate in Upcoming Investor Conferences BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients…
prnewswire.com Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones -- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction…
benzinga.com This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday 
prnewswire.com Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022…
prnewswire.com Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors -- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's…
prnewswire.com Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 -- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction…
prnewswire.com Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients…
prnewswire.com Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements -- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile…
zacks.com What Makes Elevation Oncology (ELEV) a New Strong Buy Stock Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
benzinga.com S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates - benzinga.com Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
- benzinga.com Dow Jumps Over 300 Points; US Trade Gap Narrows In June
benzinga.com GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED) GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs https://www.hhs.gov/about/news/2024/03/26/hhs-announces-savings-41-prescription-drugs-thanks-inflation-rebates-from-biden-harris-administrations-lower-cost-prescription-drug-law.html
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.
- benzinga.com Why Sientra Shares Are Trading Higher By 84%; Here Are 20 Stocks Moving Premarket Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares rose 112.5% to $0.6801 in pre-market trading.
- benzinga.com Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
- benzinga.com Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.
- benzinga.com Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.
- benzinga.com Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's trading, 71 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 122 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 529 companies set new 52-week lows.